Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and...
Windlas Biotech reported revenue of 7.60 billion INR for fiscal year 2025, up 20.4% from fiscal year 2024, and net income of 609.94 million INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 2.33 billion INR, up 19.5% from a year before. India was its largest region in fiscal year 2025, with 96% of revenue. Its market capitalization was 19.59 billion INR as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 9, 2026.
No profile data available.